Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combination With Chemotherapy With/Without Bevacizumab for Hepatic Metastases From Colorectal Cancer

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Mount Sinai Hospital, New York
Mount Sinai School of Medicine
Information provided by (Responsible Party):
Memorial Sloan-Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT00200200
First received: September 12, 2005
Last updated: November 21, 2014
Last verified: November 2014

September 12, 2005
November 21, 2014
November 2004
November 2015   (final data collection date for primary outcome measure)
To determine whether the addition of concurrent intravenous bevacizumab to HAI plus systemic chemotherapy increases the time to progression in patients with completely resected hepatic metastases from colorectal cancer [ Time Frame: 7.5 months ] [ Designated as safety issue: No ]
To determine whether the addition of concurrent intravenous Bevacizumab to HAI plus systemic chemotherapy increases the time to progression in patients with completely resected hepatic metastases from colorectal cancer.
Complete list of historical versions of study NCT00200200 on ClinicalTrials.gov Archive Site
  • To assess toxicity [ Time Frame: 7.5 months ] [ Designated as safety issue: No ]
  • To determine survival [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • To assess the expression pattern of VEGFR1, VEGFR2 (angiogenesis), and VEGFR3 (lymphangiogenesis) and their cognate ligands (VEGF-A, VEGF-C, VEGF-D), and correlate with patient progression and survival following [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • To compare plasma levels of VEGF-A, VEGF-C, VEGF-D, and CD133+ VEGFR2+ circulating endothelial progenitors [ Time Frame: 2 years ] [ Designated as safety issue: No ]
To assess toxicity. To determine survival. To assess the expression pattern of VEGFR1, VEGFR2 (angiogenesis), and VEGFR3 (lymphangiogenesis) and their cognate ligands (VEGF-A, VEGF-C, VEGF-D), and correlate with patient progression and survival following
Not Provided
Not Provided
 
Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combination With Chemotherapy With/Without Bevacizumab for Hepatic Metastases From Colorectal Cancer
Randomized Ph II Study of Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combination With IV Systemic Chemo With/Without Bevacizumab (mAB to Vascular Endothelial Growth Factor-A) in Patients With Resected Hepatic Metastases From Colorectal Cancer

The purpose of this study is to determine whether the addition of bevacizumab, to hepatic arterial therapy with floxuridine (FUDR) and dexamethasone (Dex) (regional chemotherapy), and either oxaliplatin or CPT-11, plus 5-fluorouracil and leucovorin (systemic chemotherapy) will increase disease free survival in patients who have undergone liver resection. The patient will be randomized (a computer generated decision as in the flip of a coin) to receive, or not to receive bevacizumab in addition to regional and systemic chemotherapy.

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Hepatic Metastases
  • Colon Cancer
  • Rectal Cancer
  • Drug: Bevacizumab HAI plus systemic chemotherapy
    Oxaliplatin (mg/m2) IV, over 2 hours, 5 FU (mg/m2) continuous infusion, over two days, leucovorin (mg/m2) IV, over 2 hours
  • Drug: HAI plus systemic chemotherapy
    Irinotecan (mg/m2) IV, over 30 minutes, 5 FU (mg/m2) continuous infusion over two days, leucovorin (mg/m2) IV, over 30 minutes
  • Active Comparator: 1
    Bevacizumab in addition to HAI plus systemic chemotherapy
    Intervention: Drug: Bevacizumab HAI plus systemic chemotherapy
  • Experimental: 2
    HAI plus systemic chemotherapy alone
    Intervention: Drug: HAI plus systemic chemotherapy
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
73
November 2015
November 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • History of histologically confirmed colorectal adenocarcinoma metastatic to the liver with no clinical or radiographic evidence of extrahepatic disease. Confirmation of diagnosis must be performed at MSKCC.
  • Potentially completely resectable hepatic metastases without current evidence of other metastatic disease.
  • Abdominal and pelvic CT scans and chest CT or x-ray within 6 weeks prior to registration. (MRI of abdomen may be substituted for CT of abdomen.)
  • Lab values within 14 days prior to registration:

    • WBC ≥ 3.0 K/uL
    • ANC > 1.5 K/uL
    • Platelets ≥ 75 K/uL
    • Total bilirubin < 1.5 mg/dL
    • INR < 1.5
    • Creatinine < 2.0 mg/dL
    • HGB ≥ 9 gm/dL
  • Prior chemotherapy is acceptable if last dose given ≥ 3 weeks prior to registration to this study. [Note: no chemotherapy to be given after resection of liver lesions prior to treatment on this study.]
  • KPS ≥ 70%
  • Signed informed consent
  • Patient age must be >18

Exclusion Criteria:

  • Prior radiation to the liver. (Prior radiation therapy to the pelvis is acceptable if completed at least 4 weeks prior to registration.)
  • Active infection, ascites, hepatic encephalopathy.
  • Prior treatment with HAI FUDR.
  • Female patients who are pregnant or lactating.
  • Subjects discovered to have ≥1+ proteinuria at baseline will undergo a 24-hour urine collection, which must be an adequate collection and must demonstrate <1 g of protein/24 hours to allow participation in this study.
  • Patients may not be receiving any other investigational agents
  • Patients with known brain metastases that would confound the evaluation of neurologic and other adverse events will be excluded. Patients with history of primary CNS tumors, seizures not well-controlled with standard medical therapy, or history of stroke will also be excluded.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to bevacizumab.
  • Serious or non-healing active wound, ulcer, or bone fracture
  • Major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to Day 1 of protocol treatment. (Surgery performed to resect metastatic lesions and place pump will not exclude patient from protocol; Day 1 of protocol treatment will take place no sooner than 28 days after surgery.)
  • Current or recent use of a thrombolytic agent.
  • Chronic daily treatment with aspirin (> 325 mg/d) or nonsteroidal anti-inflammatory medications known to inhibit the platelet function.
  • Presence of bleeding diathesis or coagulopathy.
  • History of serious systemic disease, including myocardial infarction within the last 12 months, uncontrolled hypertension (blood pressure of > 160/110 mmHg on medication), unstable angina within the last 12 months, New York Heart Association (NYHA) Grade II or greater congestive heart failure (see Appendix C), unstable symptomatic arrhythmia requiring medication (subjects with chronic atrial arrhythmia, i. e. atrial fibrillation or paroxysmal supraventricular tachycardia are eligible), or peripheral vascular disease (Grade II or greater).
  • Patients with a history of stroke or transient ischemic attack.
  • Presence of central nervous system or brain metastases.
  • Patients who have a diagnosis of Gilbert's disease.
Both
19 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00200200
04-086
Not Provided
Memorial Sloan-Kettering Cancer Center
Memorial Sloan-Kettering Cancer Center
  • Mount Sinai Hospital, New York
  • Mount Sinai School of Medicine
Principal Investigator: Nancy Kemeny, M.D Memorial Sloan-Kettering Cancer Center
Memorial Sloan-Kettering Cancer Center
November 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP